• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Ryanair Holdings Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session

    7/24/23 2:54:54 PM ET
    $AMC
    $APLD
    $APPH
    $ARMP
    Movies/Entertainment
    Consumer Discretionary
    Finance: Consumer Services
    Finance
    Get the next $AMC alert in real time by email

    Gainers

    • Tupperware Brands Corporation (NYSE:TUP) shares jumped 59% to $1.43 on above-average volume amid retail investor interest.
    • Vinco Ventures, Inc. (NASDAQ:BBIG) gained 51.4% to $5.04.
    • Spark Networks SE (NYSE:LOV) jumped 25.5% to $0.2862.
    • AMC Entertainment Holdings, Inc. (NYSE:AMC) shares surged 25% to $5.51 after a Delaware judge denied the company from converting its AMC preferred equity units into common stock.
    • Applied Digital Corporation (NASDAQ:APLD) gained 23.4% to $9.53 after the company reported better-than-expected fourth-quarter adjusted EPS results and issued FY24 revenue guidance above estimates.
    • BioNexus Gene Lab Corp. (NASDAQ:BGLC) shares rose 22.2% to $5.95 after gaining 22% on Friday.
    • Knightscope, Inc. (NASDAQ:KSCP) gained 21.6% to $1.4593. Knightscope received letter of compliance from the Nasdaq.
    • Superior Drilling Products, Inc. (NYSE:SDPI) jumped 20.8% to $2.1750.
    • Jaguar Health, Inc. (NASDAQ:JAGX) gained 19.6% to $0.67.
    • Steakholder Foods Ltd. (NASDAQ:STKH) rose 19% to $1.00. Steakholder Foods Ltd entered into a Memorandum of Agreement for Strategic Cooperation (MOA) with an accredited GCC-based governmental body as its strategic partner.
    • Marker Therapeutics, Inc. (NASDAQ:MRKR) gained 18.6% to $7.84.
    • Armata Pharmaceuticals, Inc. (NYSE:ARMP) shares gained 17.4% to $1.35.
    • Koss Corporation (NASDAQ:KOSS) shares gained 17.3% to $4.24.
    • POSCO Holdings Inc. (NYSE:PKX) shares gained 17.2% to $124.43 following strong quarterly earnings.
    • HighPeak Energy, Inc. (NASDAQ:HPK) rose 16% to $15.02.
    • PaxMedica, Inc. (NASDAQ:PXMD) jumped 16% to $0.9382 after the company reported topline results from PAX-101 (intravenous suramin) Phase 3 African sleeping sickness study.
    • Educational Development Corporation (NASDAQ:EDUC) surged 16% to $1.8011.
    • Dragonfly Energy Holdings Corp. (NASDAQ:DFLI) gained 14.6% to $2.8599.
    • NIO Inc. (NYSE:NIO) jumped 12.5% to $11.91. Shares of several Chinese companies traded higher after China earlier announced it has pledged to optimize the business environment for private enterprises ahead of the Politburo meeting later this week.
    • Yellow Corporation (NASDAQ:YELL) jumped 12.2% to $1.1899.
    • Metropolitan Bank Holding Corp. (NYSE:MCB) gained 8.6% to $45.46. Metropolitan Bank Holding recently reported worse-than-expected second-quarter financial results.
    • Becton, Dickinson and Company (NYSE:BDX) rose 6.2% to $281.35 after the company announced it received FDA510(k) clearance for the updated BD Alaris Infusion System. Also, Raymond James upgraded the stock from Market Perform to Outperform with a $305 price target.

    Losers

    • AppHarvest, Inc. (NASDAQ:APPH) shares fell 69.9% to $0.1009. AppHarvest announced Chapter 11 filing to support a financial and operational transition.
    • Kodiak Sciences Inc. (NASDAQ:KOD) fell 47.7% to $3.8215 after the company released topline results from three Phase 3 studies of tarcocimab tedromer for neovascular age-related macular degeneration and diabetic macular edema.
    • BioCardia, Inc (NASDAQ:BCDA) declined 44.4% to $1.1001.
    • 22nd Century Group, Inc. (NYSE:XXII) fell 43.1% to $2.7583. 22nd Century named interim CEO and implemented a $15 million cost reduction initiative.
    • ViewRay, Inc. (NASDAQ:VRAY) fell 28.6% to $0.0421 after the company reported commencement of Nasdaq delisting proceedings. The company’s common stock is expected to begin trading on the over-the counter markets.
    • Contango Ore, Inc. (NYSE:CTGO) fell 27.1% to $19.33 after the company reported an underwritten public offering of common stock.
    • Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) shares fell 39.5% to $0.1337 MEI Pharma failed to secure stockholder approval for the merger deal with Infinity Pharmaceuticals.
    • Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) fell 30.1% to $5.18 after the company announced non-binding term sheet for up to $125 million debt financing.
    • Quince Therapeutics, Inc. (NASDAQ:QNCX) fell 26.9% to $1.1550. Quince Therapeutics agreed to acquire EryDel SpA, a privately-held, late-stage biotech company, in a stock-for-stock upfront exchange and potential downstream milestone cash payments.
    • Guardforce AI Co., Limited (NASDAQ:GFAI) declined 25.7% to $6.24.
    • Carmell Therapeutics Corporation (NASDAQ:CTCX) fell 22% to $4.2850.
    • TMC the metals company Inc. (NASDAQ:TMC) fell 21.7% to $1.4250.
    • DarioHealth Corp. (NASDAQ:DRIO) fell 17.1% to $3.5050 after the company reported preliminary second-quarter preliminary revenue results below the estimate.
    • Lifezone Metals Limited (NYSE:LZM) declined 16.2% to $9.05.
    • Stoke Therapeutics, Inc. (NASDAQ:STOK) fell 16% to $10.08
    • Digital World Acquisition Corp. (NASDAQ:DWAC) shares fell 15.1% to $17.05. Digital World Acquisition shares jumped over 50% on Friday after the company announced it reached a settlement with the SEC.
    • Biomea Fusion, Inc. (NASDAQ:BMEA) declined 14.7% to $18.37 as the company released preliminary topline data from its ongoing Phase 1 COVALENT-101 trial, showcasing initial responses in relapsed/refractory AML patients with menin-dependent mutations.
    • INVO Bioscience, Inc. (NASDAQ:INVO) fell 14.4% to $0.1420.
    • Liquidia Corporation (NASDAQ:LQDA) declined 13.8% to $7.03.
    • PSQ Holdings, Inc. (NYSE:PSQH) fell 12.4% to $18.50 after declining 29% on Friday. Trading of PublicSq.'s shares of Class A common stock commencedThursday following the successful completion of its previously announced business combination with Colombier Acquisition Corp.
    • Camber Energy, Inc. (NYSE:CEI) shares fell 11.6% to $1.0787. Camber Energy shares gained 53% on Friday after the company and Viking Energy announced shareholder approval of the merger.
    • ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) fell 9.9% to $0.1788 as the company announces pricing of $2.1 million public offering of 12,727,273 shares of common stock and warrants at a price of $0.165 per unit.
    • fuboTV Inc. (NASDAQ:FUBO) fell 9.6% to $2.4950.
    • E-Home Household Service Holdings Limited (NASDAQ:EJH) fell 9% to $0.1146.
    • Ryanair Holdings plc (NASDAQ:RYAAY) fell 8.3% to $98.59 after the company reported quarterly results.

     

    Now Read This: Check Out 3 High-Yielding Dividend Stocks In Tech And Telecom Sector From Wall Street's Most Accurate Analysts

    Get the next $AMC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMC
    $APLD
    $APPH
    $ARMP

    CompanyDatePrice TargetRatingAnalyst
    NIO Inc.
    $NIO
    3/13/2026$6.80Hold → Buy
    HSBC Securities
    Ryanair Holdings plc
    $RYAAY
    3/12/2026$80.00In-line → Outperform
    Evercore ISI
    NIO Inc.
    $NIO
    3/11/2026$6.60Neutral → Buy
    Nomura
    Stoke Therapeutics Inc.
    $STOK
    2/24/2026$40.00Outperform
    Wolfe Research
    Ryanair Holdings plc
    $RYAAY
    2/18/2026Buy → Hold
    Erste Group
    Becton Dickinson and Company
    $BDX
    2/10/2026$202.00Overweight
    Barclays
    Stoke Therapeutics Inc.
    $STOK
    2/5/2026$60.00Buy
    Guggenheim
    FuboTV Inc.
    $FUBO
    2/5/2026$3.00Neutral → Buy
    Seaport Research Partners
    More analyst ratings

    $AMC
    $APLD
    $APPH
    $ARMP
    SEC Filings

    View All

    Armata Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)

    3/19/26 7:10:20 AM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 20-F filed by Lifezone Metals Limited

    20-F - Lifezone Metals Ltd (0001958217) (Filer)

    3/19/26 6:59:42 AM ET
    $LZM
    Metal Mining
    Basic Materials

    SEC Form 10-K filed by DarioHealth Corp.

    10-K - DarioHealth Corp. (0001533998) (Filer)

    3/19/26 6:05:44 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $AMC
    $APLD
    $APPH
    $ARMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NIO upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded NIO from Hold to Buy and set a new price target of $6.80

    3/13/26 8:42:10 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    Ryanair Hldgs upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Ryanair Hldgs from In-line to Outperform and set a new price target of $80.00

    3/12/26 8:41:27 AM ET
    $RYAAY
    Air Freight/Delivery Services
    Consumer Discretionary

    NIO upgraded by Nomura with a new price target

    Nomura upgraded NIO from Neutral to Buy and set a new price target of $6.60

    3/11/26 8:29:36 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    $AMC
    $APLD
    $APPH
    $ARMP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CJ 4DPLEX and AMC Theatres Launch First Four Premium SCREENX and 4DX Locations in the United States

    AMC Burbank 16 in the Los Angeles market, AMC Town Square 18 in Las Vegas, AMC Gulf Pointe 30 in Houston, and AMC Barrywoods 24 in Kansas City have debuted new immersive premium formats as part of the companies' rollout to select AMC locations.BURBANK, Calif., March 19, 2026 /CNW/ -- CJ 4DPLEX, the world's leading producer of premium cinema formats and immersive theater technologies, and AMC Theatres (NYSE:AMC), the largest theatrical exhibitor in the United States and the world, today announced the opening of the first four premium format auditoriums developed under their strategic partnership. Two SCREENX at AMC auditoriums and two 4DX at AMC auditoriums have been completed across key loca

    3/19/26 9:30:00 AM ET
    $AMC
    Movies/Entertainment
    Consumer Discretionary

    Lifezone Metals Announces 2025 Financial Results and Filing of Form 20-F

    Lifezone Metals Limited's (NYSE:LZM) Chief Executive Officer, Chris Showalter and Chief Financial Officer, Ingo Hofmaier, announce the full-year 2025 financial results and the filing of Lifezone's Annual Report on Form 20-F with the U.S. Securities and Exchange Commission, available on Edgar and the Company's website. Mr. Hofmaier commented: "Throughout 2025, we continued to advance the high-grade Kabanga Nickel Project, amid a challenging nickel market, which included the filing of a Feasibility Study with strong economics, raising $60 million from Taurus Mining Finance and $15 million in equity from U.S. investors, demonstrating the quality, scale, and long-term potential of the Kabanga

    3/19/26 7:04:00 AM ET
    $LZM
    Metal Mining
    Basic Materials

    Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update

    LOS ANGELES, March 19, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it will delay the announcement of its financial results for its fourth quarter and full-year ended December 31, 2025, and provided a corporate update. The Company requires additional time to complete its financial reporting and ant

    3/19/26 7:00:00 AM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMC
    $APLD
    $APPH
    $ARMP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Financial Officer Dougherty Daniel F bought $79,950 worth of shares (1,000 units at $79.95), increasing direct ownership by 3% to 32,197 units (SEC Form 4)

    4 - Metropolitan Bank Holding Corp. (0001476034) (Issuer)

    3/11/26 5:05:05 PM ET
    $MCB
    Major Banks
    Finance

    President and CEO Altman Peter bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 2% to 273,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    2/4/26 5:47:41 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,194 worth of shares (900 units at $1.33), increasing direct ownership by 0.34% to 268,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    1/21/26 5:03:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMC
    $APLD
    $APPH
    $ARMP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for YCANTH issued to VERRICA PHARMACEUTICALS INC

    Submission status for VERRICA PHARMACEUTICALS INC's drug YCANTH (ORIG-1) with active ingredient CANTHARIDIN has changed to 'Approval' on 07/21/2023. Application Category: NDA, Application Number: 212905, Application Classification: Type 5 - New Formulation or New Manufacturer

    7/21/23 4:54:32 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

    For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

    11/23/21 3:16:12 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $AMC
    $APLD
    $APPH
    $ARMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Mcguinness Jason Paul

    3 - RYANAIR HOLDINGS PLC (0001038683) (Issuer)

    3/18/26 8:09:33 PM ET
    $RYAAY
    Air Freight/Delivery Services
    Consumer Discretionary

    SEC Form 3 filed by new insider Mcmahon Neal

    3 - RYANAIR HOLDINGS PLC (0001038683) (Issuer)

    3/18/26 8:09:03 PM ET
    $RYAAY
    Air Freight/Delivery Services
    Consumer Discretionary

    SEC Form 3 filed by new insider Sharkey Carol Marie

    3 - RYANAIR HOLDINGS PLC (0001038683) (Issuer)

    3/18/26 8:08:36 PM ET
    $RYAAY
    Air Freight/Delivery Services
    Consumer Discretionary

    $AMC
    $APLD
    $APPH
    $ARMP
    Leadership Updates

    Live Leadership Updates

    View All

    Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

    Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine highlighted promising results of multi-antigen targeted T cells in pancreatic cancer Strengthened manufacturing capabilities through collaboration with Cellipont Bioservices and expanded Board of Directors with appointment of Kathryn Penkus Corzo HOUSTON, March 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors, today a

    3/18/26 5:31:30 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

    Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), today announced the completion of a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd. ("Chemrex"). As part of this restructuring, Chemrex's board has been streamlined to two directors: Matthew L. Barsing, ChairmanAngeline Chong, Chief Financial Officer of BioNexus, Director New officers are expected to be appointed in the coming months. Chemrex remains a wholly owned private subsidiary of BioNexus and operates un

    2/23/26 8:30:00 AM ET
    $BGLC
    Medical Specialities
    Health Care

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AMC
    $APLD
    $APPH
    $ARMP
    Financials

    Live finance-specific insights

    View All

    DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 20252025 full-year revenue was $22.4 million, compared to $27.0 million in 2024, due entirely to a scope change and nonrenewal from a single legacy client that came through the Twill, Inc. ("Twill") acquisition — unrelated to demand — partially offset by organic revenue growth The 2025 sales season — Dario's strongest on record — generated $12.9 million in contracted and late stage, annual recurring revenue ("ARR")  set to contribute revenue in 2026 and 2027 and position the Company for a high-growth trajectoryGAAP gross margins increased to 57% in 2025 from 49% in 2024 and Non-

    3/19/26 6:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    PSQ Holdings, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Operating Improvements and Strengthened Cash Discipline

    Fourth Quarter Revenue Growth of 109% Full-Year Revenue Growth of 81% Full-Year Operating Expense Reduction of 21% PSQ Holdings, Inc. (NYSE:PSQH) (the "Company"), a payments and financial infrastructure company, today reported financial results for the fourth quarter 2025 and full year 2025. FOURTH QUARTER 2025 HIGHLIGHTS Net revenue from continuing operations, which includes the financial technology ("fintech") segment, for the quarter ended December 31, 2025 was $7.3 million compared to $3.5 million for the fourth quarter ended December 31, 2024, a 109% increase compared to the prior year period. Operating expense (defined as general and administrative, sales and marketing,

    3/17/26 6:30:00 AM ET
    $PSQH
    Advertising
    Consumer Discretionary

    Lifezone Announces Release Date of 2025 Financial Results and Notice of Financial Results Investor Webcast

    Lifezone Metals Limited (NYSE:LZM) announced today that it plans to release its Full Year 2025 financial results and file its 20-F with the U.S. Securities and Exchange Commission on March 19, 2026. Investor Webcast: March 19, 2026 / 10:00 a.m. ET | 14:00 p.m. GMT Chris Showalter, CEO and Ingo Hofmaier, CFO, will be hosting a conference call and Q&A on the day. Analysts and investors can register at: Lifezone Metals 2025 Financial Results Webcast. If you would like to sign up for Lifezone Metals news alerts, please register here. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE:LZM) is committed to delivering cleaner and more responsible metals p

    3/16/26 1:23:00 PM ET
    $LZM
    Metal Mining
    Basic Materials

    $AMC
    $APLD
    $APPH
    $ARMP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by DarioHealth Corp.

    SC 13G - DarioHealth Corp. (0001533998) (Subject)

    12/13/24 4:05:12 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by PSQ Holdings Inc.

    SC 13G - PSQ Holdings, Inc. (0001847064) (Subject)

    12/12/24 11:50:43 AM ET
    $PSQH
    Advertising
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

    SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    12/9/24 6:22:49 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care